BioNTech’s May Gauntlet: Earnings, a Shareholder Vote, and an Insider Sale Set the Stage

The first half of May is shaping up as a critical inflection point for BioNTech, with the German biotech facing a packed calendar that could redefine investor sentiment. Between a quarterly earnings release, a virtual annual general meeting, and a notable insider share sale, the company’s pivot from COVID-19 vaccine dominance to oncology specialist is being tested on multiple fronts.

The stock closed at €88.75 on Friday, just above its 200-day moving average of €87.88. While the shares have clawed back roughly 16% over the past month, they remain in negative territory year-to-date. The March low of €72.50 now looks distant, but the stock is still trading well below the average analyst price target of $133.13.

A Revenue Guidance Gap Sets the Tone

BioNTech’s first-quarter results, due on May 5, arrive with expectations already tempered. The company’s full-year 2026 revenue forecast of €2.0 billion to €2.3 billion fell well short of the market’s prior consensus of around €2.7 billion. That guidance implies a sharp decline from the nearly €2.9 billion generated in 2025, driven largely by shrinking COVID-19 vaccine sales in Europe and the US as competition intensifies.

Investors will be scrutinizing whether the first quarter at least supports the lower end of that range. The earnings call will also be the first chance for management to explain how it plans to bridge the gap between current revenue and the pipeline-driven future that underpins the stock’s valuation.

Insider Sale Adds a Subplot

Adding a layer of intrigue, BioNTech’s COO Sierk Poetting sold 50,000 shares on April 22 at an average price of $110.56, netting approximately $5.5 million. The transaction was executed under a pre-arranged 10b5-1 trading plan, distinguishing it from opportunistic insider selling. Still, the timing — just days before a pivotal earnings week — is unlikely to go unnoticed by the market.

Shareholder Vote Looms with Dilution Risk

Ten days after the earnings release, on May 15, BioNTech will hold its virtual annual general meeting. The agenda includes a proposal to expand the supervisory board from six to eight members, adding two specialists in oncology and clinical development — a clear nod to the company’s strategic shift.

Should investors sell immediately? Or is it worth buying BioNTech?

The most consequential item for shareholders, however, is a proposed capital authorization. The company is seeking approval for new authorized capital of up to €129.5 million, representing 50% of the current share capital. If utilized, this would dilute existing holders. Management has not signaled an immediate need for the authorization, but the size of the potential dilution is significant.

Also on the ballot is a domination and profit transfer agreement with subsidiary BioNTech Discovery GmbH, aimed at enabling tax loss offsetting between the parent and its unit. Given the parent company’s net loss of €1.14 billion in 2025, this is more than a procedural formality.

Pipeline Progress as the Real Story

Beyond the near-term numbers, the focus remains squarely on BioNTech’s oncology pipeline. The company has called 2026 a “catalyst-rich year,” with seven phase 3 data readouts expected and six new phase 3 trials set to begin. In April, BioNTech reported positive phase 2 data for its antibody-drug conjugate Trastuzumab Pamirtecan in advanced endometrial cancer, and a US filing for approval is planned for later this year. In China, partner DualityBio has already submitted an application for the same drug in HER2-positive breast cancer.

The competitive landscape is also providing indirect validation. Akeso’s strong phase 3 data for its PD-1/VEGF bispecific antibody Ivonescimab in advanced lung cancer has boosted confidence in the broader antibody class, where BioNTech has its own program in development.

Analyst Views: Cautious Optimism with Cuts

Wall Street remains broadly constructive, with 13 of 18 analysts rating the stock a buy and a consensus price target of $133.13. But recent revisions suggest growing caution. BMO Capital Markets trimmed its target to $128 from $143, Jefferies cut to $138 from $151, and Leerink Partners downgraded to “Market Perform” with a $113 target, citing mixed phase 1 data for the lung cancer candidate Gotistobart, which showed higher rates of death and severe side effects in early treatment months compared to the control group.

A Well-Funded Transition

BioNTech entered the year with a cash pile of €17.2 billion, providing ample runway to fund its pipeline ambitions. The question for investors is whether that financial strength can offset the revenue decline from COVID vaccines faster than the market expects. The May 5 earnings call and the subsequent shareholder vote will offer the clearest signals yet on how quickly — and at what cost — BioNTech is making the leap to an oncology-focused future.